| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5960884 | Heart Rhythm | 2014 | 8 Pages |
Abstract
Treatment with AADs was not associated with increased morbidity or mortality in anticoagulated patients with AF. The effect of amiodarone on outcomes in patients receiving rivaroxaban requires further investigation.
Keywords
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial FibrillationAADTTRVKAINRvitamin K antagonistMyocardial infarctionemergency departmentantiarrhythmic drugAntiarrhythmic drugsCNSGastrointestinalRivaroxabanTime in therapeutic rangecentral nervous systemOutcomesconfidence intervalAtrial fibrillationhazard ratioInternational Normalized RatioWarfarin
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Benjamin A. MD, Anne S. MS, Yuliya PhD, Jonathan L. MD, Günter MD, Rod MD, Graeme J. MD, Manesh R. MD, Richard C. MD, Daniel E. MD, Werner MD, PhD, Scott D. MD, Christopher C. MD, Kenneth W. MD, Keith A.A. MBChB, Robert M. MD, Jonathan P. MD, MHS, FHRS,